Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELIEVE: Rilzabrutinib in Pemphigus Vulgaris
NCT02704429Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of rilzabrutinib in pemphigus vulgaris (PV), sponsored by Sanofi. Primary endpoints: Treatment-emergent Adverse Events at 28 weeks and Control of Disease Activity at 4 weeks. Started Jan 2016; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT02704429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704429.